Neumora Therapeutics, Inc.
NMRA
$1.63
$0.010.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.17% | -26.57% | 45.90% | -36.81% | -52.30% |
| Total Depreciation and Amortization | -88.13% | -0.63% | -5.42% | -9.83% | -6.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.69% | 27.01% | -86.22% | 51.00% | 406.66% |
| Change in Net Operating Assets | 15.82% | -114.62% | 89.66% | 2,567.23% | -277.22% |
| Cash from Operations | 6.68% | -38.40% | 2.14% | 29.91% | -81.03% |
| Capital Expenditure | -- | -- | 1,861.36% | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.62% | 129.59% | -825.71% | 558.18% | -11.72% |
| Cash from Investing | 43.01% | 129.44% | -822.37% | 559.20% | -11.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.78% | -- | 4,427.43% | -99.25% | 556.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 127.44% | 92.14% | -- |
| Cash from Financing | 595.44% | -- | 3,337.63% | -99.34% | 808.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.99% | 92.00% | -249.23% | -39.91% | -384.80% |